Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug–Drug Interactions
Open Access
- 21 October 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1335
Abstract
Background: Venetoclax (VEN), a selective B-cell lymphoma 2 inhibitor, has been increasingly used off-label in pediatric patients with hematologic malignancies. However, its pharmacokinetic characteristics in pediatric patients remain insufficiently characterized. Methods: An adult VEN physiologically based pharmacokinetic (PBPK) model was developed and extrapolated to children using age-dependent physiological and CYP3A4 ontogeny data. The pediatric model was calibrated and evaluated using data from 76 children with AML (203 plasma concentrations) and subsequently applied to assess food effects, age-related pharmacokinetic differences, and VEN dose-reduction scenarios during VCZ co-administration. The clinical study was registered with the Chinese Clinical Trial Registry (ChiCTR1900027146 and ChiCTR2400080307). Results: The adult and pediatric models adequately reproduced the observed VEN concentration–time profiles. At 200 mg/m2, a normal-fat meal increased predicted AUCinf and Cmax by 2.74- and 1.77-fold, respectively, versus a low-fat meal. Children aged 2–inf was 1.44- and 1.91-fold higher than in the 6–0–168h by 36.8% and 60.5% and Cmax by 42.5% and 70.5%, respectively, with minimal changes in Tmax. Conclusions: The pediatric VEN PBPK model quantitatively characterized the effects of meal conditions, developmental age, and VCZ-mediated CYP3A inhibition on VEN pharmacokinetics. These findings support administration with a normal diet, closer safety monitoring in children aged 2–2, and model-informed evaluation of VEN dose reduction during concomitant VCZ therapy.Keywords
This publication has 32 references indexed in Scilit:
- Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and ChallengesCPT: Pharmacometrics & Systems Pharmacology, 2025
- Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK‐Informed AnalysisThe Journal of Clinical Pharmacology, 2022
- Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and VenetoclaxPharmaceutical Research, 2022
- Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approachCancer Chemotherapy and Pharmacology, 2021
- A Retrospective Evaluation of Allometry, PopulationPharmacokinetics,andPhysiologically‐Based Pharmacokineticsfor Pediatric Dosing Using Clearance as a SurrogateCPT: Pharmacometrics & Systems Pharmacology, 2019
- Developmental Changes in Pharmacokinetics and PharmacodynamicsThe Journal of Clinical Pharmacology, 2018
- Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic ModelThe Journal of Clinical Pharmacology, 2017
- Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin LymphomaThe Journal of Clinical Pharmacology, 2016
- Applied Concepts in PBPK Modeling: How to Build a PBPK/PD ModelCPT: Pharmacometrics & Systems Pharmacology, 2016
- Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First‐in‐Class BCL‐2 InhibitorThe Journal of Clinical Pharmacology, 2016